Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nektar Therapeutics reports strong Q1 results and advances pipeline

Nektar Therapeutics demonstrated solid financial performance in Q1 2024, with a positive revenue outlook for the full year.
The company's pipeline strength lies in REZPEG's promising results, NKTR-255's progress, and the advancement of NKTR-0165.
Challenges include patient selection complexities and timing uncertainties, while opportunities exist in therapeutic optimization and pipeline expansion.
Overall, Nektar remains focused on advancing its immunology programs and leveraging its financial stability for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics (NASDAQ: NKTR) shares were crushed on Wednesday after the U.S.

Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock

In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.

FDA Advisory Committee Slams Nektar's New Opioid Drug

Nektar Therapeutics pulled its application for a pain drug called oxycodegol after a Food and Drug Administration committee rejected it — sending NKTR stock into a slide Wednesday.

How An FDA Committee Pulled The Rug Out From This Highflying Biotech

The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.

Why Nektar Therapeutics Stock Is Sinking Today

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Shares of midcap biopharma Nektar Therapeutics (NASDAQ: NKTR) are retreating sharply following a negative verdict handed down by FDA staffers for its opioid pain drug.

Nektar Slumps As FDA Panel Gives Thumbs Down To Opioid Pain Drug; Program Shelved

Nektar Therapeutics [sL nktr] shares fell in the extended session Tuesday following a report that a Food and Drug Administration advisory panel voted against recommending one of the drug maker's painkillers for approval.

Nektar stock drops more than 10% as FDA advisers say no to painkiller

Beyond Meat

Criteo

Check out the companies making headlines after the bell.

Stocks making the biggest moves after the bell: Nektar Therapeutics, Beyond Meat and Criteo

Nektar Therapeutics is a Buy, especially for investors with medium- to long-term time frame.

Nektar Therapeutics: Updates To Thesis, Bempeg To Boost Opdivo Prospects In Crowded I-O Arena

Nektar Therapeutics' experimental opioid will finally get a long-awaited date with an FDA advisory committee -- and it probably won't go smoothly.

Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee

Bristol-Myers

Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.

Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration

The company announced a new development plan with Bristol-Myers Squibb.

Here's Why Nektar Therapeutics Shares Rose as Much as 19.7% Today

Pharma giant Bristol-Myers Squibb deepened its cancer treatment partnership with Nektar Therapeutics on Friday — leading NKTR stock to pop to its highest point since August 2019.
The post Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing appeared first on Investor's Business Daily.

Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing

Four companies vied to buy or partner with Synthorx before Sanofi snapped up the biotech company for $2.5 billion, according to new filings with the Securities and Exchange Commission.

Why A Bidding War For Synthorx Bodes Well For This Biotech Stock

Atara Biotherapeutics

Boot Barn Hlds

iShares MSCI USA Momentum Factor ETF

Office Depot

SPDR Russell 1000 Momentum Focus ETF

Invesco DWA Momentum ETF

Invesco S&P 500 High Beta ETF

Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.

Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On

Alkermes

Baidu

Groupon

Signet Jewelers

The positive sentiment witnessed by Wall Street in 2019 might be prevalent in 2020 as well owing to multiple tailwinds.

5 Losing Stocks From 2019 to Rebound Next Year

Cloudera

At least this pair of winners is getting cheerful in advance of the holidays.

2 Stocks That Soared Monday While the Market Slumped

Data presentations at a major scientific conference and the acquisition of another small biotech sparked investors' enthusiasm.

Why Nektar Therapeutics Stock Popped Today

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?

Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report?

Nektar: Poised For A Rebound

Nektar Therapeutics (NASDAQ: NKTR) shares made a handy gain on Monday after the firm announced updated results from its first-in-human Phase 1a study of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions.

Why This Early-Stage Autoimmune and Chonic Inflamatory Trial May Be a Big Hit

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates.

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2019 Results - Earnings Call Transcript

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company based in San Francisco, is focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain. The stock is down by about 20% over the last month and by almost 50% in the last quarter.

News for Nektar Therapeutics Stock (NKTR)